MD Anderson and AmMax Bio Announce Agreements to Advance Development of AMB-066 in Colorectal Cancer Patients With Minimal Residual Disease
December 11, 2024
December 11, 2024
HOUSTON, Texas, Dec. 11 (TNSres) -- The University of Texas MD Anderson Cancer Center issued the following news release:
* * *
Collaboration to evaluate monoclonal antibody as first-in-class treatment in this setting
* * *
The University of Texas MD Anderson Cancer Center and AmMax Bio, Inc. today announced a worldwide exclusive license agreement and clinical trial agreement to develop and advance AmMax's AMB-066 monoclonal antibody therapy as . . .
* * *
Collaboration to evaluate monoclonal antibody as first-in-class treatment in this setting
* * *
The University of Texas MD Anderson Cancer Center and AmMax Bio, Inc. today announced a worldwide exclusive license agreement and clinical trial agreement to develop and advance AmMax's AMB-066 monoclonal antibody therapy as . . .